{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T11:01:33Z","timestamp":1792839693367,"version":"4.5.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["journal-of-hepatology.eu","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1016\/j.jhep.2015.03.014","type":"journal-article","created":{"date-parts":[[2015,3,23]],"date-time":"2015-03-23T05:44:18Z","timestamp":1427089458000},"page":"337-345","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":143,"title":["Improvement of health-related quality of life and work productivity in chronic hepatitis C patients with early and advanced fibrosis treated with ledipasvir and sofosbuvir"],"prefix":"10.1016","volume":"63","author":[{"given":"Zobair M.","family":"Younossi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Stepanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nezam","family":"Afdhal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kris V.","family":"Kowdley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Zeuzem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Henry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon L.","family":"Hunt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Marcellin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2015.03.014_b0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11894-009-0087-2","article-title":"The healthcare burden imposed by liver disease in aging Baby Boomers","volume":"12","author":"Davis","year":"2010","journal-title":"Curr Gastroenterol Rep"},{"key":"10.1016\/j.jhep.2015.03.014_b0010","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1056\/NEJMp1302973","article-title":"Hepatitis C in the United States","author":"Holmberg","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2015.03.014_b0015","doi-asserted-by":"crossref","first-page":"9633","DOI":"10.3748\/wjg.v20.i29.9633","article-title":"Hepatitis C virus in the new era: perspectives in epidemiology, prevention, diagnostics and predictors of response to therapy","volume":"20","author":"Ansaldi","year":"2014","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jhep.2015.03.014_b0020","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/apt.12625","article-title":"The impact of hepatitis C burden: an evidence-based approach","volume":"39","author":"Younossi","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2015.03.014_b0025","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.cld.2014.05.002","article-title":"Hepatitis viruses and liver transplantation: evolving trends in antiviral management","volume":"18","author":"Verna","year":"2014","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.jhep.2015.03.014_b0030","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1097\/01.aids.0000192071.72948.77","article-title":"A review of cognitive impairment and cerebral metabolite abnormalities in patients with hepatitis C infection","volume":"19","author":"Forton","year":"2005","journal-title":"AIDS"},{"key":"10.1016\/j.jhep.2015.03.014_b0035","doi-asserted-by":"crossref","first-page":"e110529","DOI":"10.1371\/journal.pone.0110529","article-title":"Hepatitis C virus infection as a traumatic experience","volume":"9","author":"Morais-de-Jesus","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2015.03.014_b0040","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1111\/j.1478-3231.2008.01719.x","article-title":"Neuropsychological function in patients with chronic hepatitis C","volume":"28","author":"Quarantini","year":"2008","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2015.03.014_b0045","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.genhosppsych.2007.08.014","article-title":"High frequency of unrecognized mental disorders in HCV-infected patients","volume":"30","author":"Batista-Neves","year":"2008","journal-title":"Gen Hosp Psychiatry"},{"key":"10.1016\/j.jhep.2015.03.014_b0050","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.jhep.2011.09.015","article-title":"Effects of anti-viral therapy and HCV clearance on cerebral metabolism and cognition","volume":"56","author":"Byrnes","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.03.014_b0055","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.jhep.2011.11.004","article-title":"Hepatitis C treatment\u2013clearing the mind","volume":"56","author":"Forton","year":"2012","journal-title":"J Hepatol"},{"issue":"Supplement S1","key":"10.1016\/j.jhep.2015.03.014_b0215","first-page":"221A","article-title":"Cerebral MR spectroscopy and patient-reported mental health outcomes in hepatitis C genotype 1 na\u00efve patients treated with ledipasvir and sofosbuvir","volume":"60","author":"Alsop","year":"2014","journal-title":"Hepatol"},{"key":"10.1016\/j.jhep.2015.03.014_b0065","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.cgh.2010.08.026","article-title":"Manifestations of chronic hepatitis C virus infection beyond the liver","volume":"8","author":"Jacobson","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2015.03.014_b0070","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/hep.20659","article-title":"Impact of hepatitis C on health related quality of life: a systematic review and quantitative assessment","volume":"41","author":"Spiegel","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.03.014_b0075","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.dld.2005.04.022","article-title":"Health-related quality of life (HRQL) in chronic liver disease","volume":"37","author":"Martin","year":"2005","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.jhep.2015.03.014_b0080","doi-asserted-by":"crossref","first-page":"253","DOI":"10.3111\/13696998.2011.566294","article-title":"The impact of hepatitis C on labor force participation, absenteeism, presenteeism and non-work activities","volume":"14","author":"DiBonaventura","year":"2011","journal-title":"J Med Econ"},{"key":"10.1016\/j.jhep.2015.03.014_b0085","first-page":"657","article-title":"Absenteeism and productivity among employees being treated for hepatitis C","volume":"17","author":"Brook","year":"2011","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.jhep.2015.03.014_b0090","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1002\/hep.23726","article-title":"The impact of hepatitis C virus infection on work absence, productivity, and healthcare benefit costs","volume":"52","author":"Su","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.03.014_b0095","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1007\/s10620-006-9708-x","article-title":"Fatigue and health-related quality of life (HRQL) in chronic hepatitis C virus infection","volume":"52","author":"Kallman","year":"2007","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jhep.2015.03.014_b0100","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/S0168-8278(00)00026-X","article-title":"The effects of interferon alpha-2b in combination with ribavirin on health related quality of life and work productivity","volume":"34","author":"McHutchison","year":"2001","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.03.014_b0105","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1002\/hep.21565","article-title":"The effects of HCV infection and management on health-related quality of life","volume":"45","author":"Younossi","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.03.014_b0110","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1111\/j.1365-2036.2010.04235.x","article-title":"Changes in quality of life and sexual health are associated with low-dose peginterferon therapy and disease progression in patients with chronic hepatitis C","volume":"31","author":"Snow","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2015.03.014_b0115","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.jhep.2006.10.009","article-title":"Health-related quality of life in patients with chronic hepatitis C and advanced fibrosis","volume":"46","author":"Bonkovsky","year":"2007","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.03.014_b0120","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/j.1478-3231.2010.02378.x","article-title":"Impact of a sustained virological response on the long-term outcome of hepatitis C","volume":"31","author":"Alberti","year":"2011","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2015.03.014_b0125","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/hep.510300203","article-title":"Health-related quality of life in chronic hepatitis C: impact of disease and treatment response. The Interventional Therapy Group","volume":"30","author":"Ware","year":"1999","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.03.014_b0130","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1002\/hep.22759","article-title":"Diagnosis, management, and treatment of hepatitis C: an update","volume":"49","author":"Ghany","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.03.014_b0135","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1111\/jvh.12080","article-title":"Knowledge about infection is the only predictor of treatment in patients with chronic hepatitis C","volume":"20","author":"Younossi","year":"2013","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2015.03.014_b0140","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1002\/hep.27161","article-title":"Patient-reported outcomes in chronic hepatitis C patients with cirrhosis treated with sofosbuvir-containing regimens","volume":"59","author":"Younossi","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.03.014_b0145","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJMoa1402454","article-title":"Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection","volume":"370","author":"Afdhal","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2015.03.014_b0150","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1056\/NEJMoa1316366","article-title":"Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection","volume":"370","author":"Afdhal","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2015.03.014_b0155","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1056\/NEJMoa1402355","article-title":"Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis","volume":"370","author":"Kowdley","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2015.03.014_b0160","doi-asserted-by":"crossref","unstructured":"Younossi Z, Stepanova M, Marcellin, Afdhal N, Kowdley K, Zeuzem S, Hunt S. Treatment with interferon and ribavirin-free regimens with ledipasvir and sofosbuvir improves patient-reported outcomes for patients with genotype 1 chronic hepatitis C: results from the ION-1, 2 and 3 clinical trials. (Abstract): AASLD 2014.","DOI":"10.1002\/hep.27724"},{"key":"10.1016\/j.jhep.2015.03.014_b0165","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1023\/A:1012588218728","article-title":"Interpreting SF-36 summary health measures: a response","volume":"10","author":"Ware","year":"2001","journal-title":"Qual Life Res"},{"key":"10.1016\/j.jhep.2015.03.014_b0170","first-page":"604","article-title":"The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: validation of version 4 of the core questionnaire","volume":"8","author":"Webster","year":"1999","journal-title":"Qual Life Res"},{"key":"10.1016\/j.jhep.2015.03.014_b0175","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.dld.2005.04.022","article-title":"Health-related quality of life (HRQOL) in chronic liver disease","volume":"37","author":"Martin","year":"2005","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.jhep.2015.03.014_b0180","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","article-title":"The validity and reproducibility of a work productivity and activity impairment instrument","volume":"4","author":"Reilly","year":"1993","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jhep.2015.03.014_b0185","first-page":"14","article-title":"Revised SF-6D scoring programmes: a summary of improvements","volume":"40","author":"Brazier","year":"2008","journal-title":"PRO Newsletter"},{"key":"10.1016\/j.jhep.2015.03.014_b0190","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/hep.510240201","article-title":"An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group","volume":"24","author":"Bedossa","year":"1996","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.03.014_b0195","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.jhep.2013.12.006","article-title":"Minimal impact of sofosbuvir and ribavirin on health related quality of life in Chronic Hepatitis C (CH-C)","volume":"60","author":"Younossi","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.03.014_b0200","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/j.cgh.2013.11.032","article-title":"Effects of sofosbuvir-based treatment, with and without interferon, on outcome and productivity of patients with chronic hepatitis C","volume":"12","author":"Younossi","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2015.03.014_b0205","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.jhep.2014.04.003","article-title":"Patient-reported outcomes assessment in chronic hepatitis C treated with sofosbuvir and ribavirin: The VALENCE study","volume":"61","author":"Younossi","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.03.014_b0210","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/apt.12880","article-title":"Patients\u2019 preferences and health utility assessment with SF-6D and EQ-5D in patients with chronic hepatitis C treated with sofosbuvir regimens","volume":"40","author":"Stepanova","year":"2014","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827815001920?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827815001920?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,22]],"date-time":"2019-08-22T03:46:26Z","timestamp":1566445586000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827815001920"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["S0168827815001920"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2015.03.014","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.725398631.793505245","asserted-by":"object"}]},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2015,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Improvement of health-related quality of life and work productivity in chronic hepatitis C patients with early and advanced fibrosis treated with ledipasvir and sofosbuvir","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2015.03.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2015.05.004","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}